|
|
Abstract
INTERLEUKIN-2 THERAPY IN HIV-1 INFECTED ARV NAIVE PATIENTS: EFFECT ON T CELL ACTIVATION.
SULLIVAN A, AMJADI P, NELSON M, TAVEL J, GOTCH F, YOULE M, GAZZARD B
Objective:To determine the effect of IL-2 therapy on T cell phenotype in ARV naïve, HIV-1 infected patients.
Methods:HIV-1 infected ARV naive individuals with CD4 T cell counts>350cells/?l were enrolled as part of a multicentre, randomised, open-label, controlled trial of IL-2 therapy (UK Vanguard). IL-2 regimen was 4.5 or 7.5 MU sc bd for 5 days; three 8 weekly cycles. Samples for viral load and T cell subsets were obtained on days 1, 5 and 29 of each cycle.
Results:Five patients received 12 IL-2 cycles (4 at 4.5MU, 1 at 7.5MU). One patient was lost to follow-up after one cycle and one patient did not receive his third cycle (pancreatitis complicating cycles 1 (7.5MUbd) and 2 (4.5MUbd)). Overall the median CD4 cell count rose from 407 to 664 cells/?l and the median viral load did not change. For all IL-2 cycles comparing day one to day five a rise was seen in the percentage of CD4+HLADR+, CD8+HLADR+, CD8+38+, CD4+25+ and CD8+25+ T cells, all returned to baseline by day 29 following each cycle. A fall was seen in CD8+45RA+ cell % on day five, returning to baseline by day 29 of follow-up. The mean intensity of receptor expression rose on day 5 for CD38 receptors on CD4 and CD8 cells and CD25 on the CD4 subset, returning to baseline by day 56 following each cycle.
Conclusions:CD4 and CD8 activation markers rose acutely and transiently following IL-2 therapy in HIV-1 infected patients not receiving HAART, returning to baseline within 4 weeks. CD25 also rose transiently in response to IL-2 therapy in the absence of HAART. No adverse effect on viral load was seen in this subset or in the Vanguard study population, although a transient rise in viral load was seen in the Vanguard UK patient cohort on day 5. Concerns regarding sustained upregulation of viral replication appear not to be borne out in this small study, and would suggest IL-2 can be given in ARV naïve patients without a sustained adverse effect on the viral load or T cell activation.
The 1st. IAS Conference on HIV Pathogenesis and Treatment
Abstract no.
109
Suggested Citation
"SULLIVANA, et al.
INTERLEUKIN-2 THERAPY IN HIV-1 INFECTED ARV NAIVE PATIENTS: EFFECT ON T CELL ACTIVATION..
Oral Presentation:
The 1st. IAS Conference on HIV Pathogenesis and Treatment
:
Abstract no.
109"
|
|
|